Director Vimal Kavuru awarded 10,000 options at Grace Therapeutics (GRCE)

Rhea-AI Filing Summary

Grace Therapeutics, Inc. director Vimal Kavuru reported a grant of stock options on January 8, 2026. He received a stock option to buy 10,000 shares of Grace Therapeutics common stock at an exercise price of $3.8 per share, held in direct ownership. Following this grant, he beneficially owns options for 10,000 shares.

According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, provided he continues to serve the company through each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kavuru Vimal

(Last) (First) (Middle)

C/O GRACE THERAPEUTICS, INC.

103 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Grace Therapeutics, Inc. [ GRCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.8	01/08/2026		A		10,000		(1)	01/08/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. 25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date.

	/s/ Robert DelAversano as attorney-in-fact for Vimal Kavuru	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who reported this insider transaction at Grace Therapeutics (GRCE)?

The reporting person is Vimal Kavuru, who serves as a director of Grace Therapeutics, Inc.

What type of security did Vimal Kavuru receive from Grace Therapeutics (GRCE)?

He received a stock option (right to buy) covering 10,000 shares of Grace Therapeutics common stock.

What is the exercise price of the 10,000 stock options granted to Vimal Kavuru at Grace Therapeutics (GRCE)?

The stock options have an exercise price of $3.8 per share for the underlying Grace Therapeutics common stock.

How do the stock options granted to director Vimal Kavuru at Grace Therapeutics (GRCE) vest?

Per the footnote, 25% vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th of each month until September 30, 2026, subject to his continuous service.

How many derivative securities does Vimal Kavuru beneficially own after this transaction at Grace Therapeutics (GRCE)?

After the reported grant, he beneficially owns 10,000 stock options, held in direct ownership.

Was the reported Grace Therapeutics (GRCE) transaction a purchase, sale, or grant?

The transaction is coded "A", indicating an acquisition of derivative securities in the form of a stock option grant.